Timmerman: Biotech success demands guts

With the odds stacked against them, intrepid biotech entrepreneurs have weathered the risky nature of drug development for decades in hopes of having an unlikely success. In these troubled financial times, however, Xconomy's Luke Timmerman writes today that developers need to keep their nerve to maintain their edge in this difficult industry. Indeed, behind some of the industry's successful drugs are those who wanted to quit on the drugs during development and those who championed further testing of the treatments. Column

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.